Original ArticleDesign of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery
Section snippets
Materials
Amphotericin-B (AmB) was kindly supplied as a gift sample by Asence Pharma Pvt. Ltd. (Vadodara, India). Eudragit RL 100 was obtained as gift sample from FDC Ltd. (Mumbai, India). Acetone, dimethyl sulfoxide (DMSO), and methanol were purchased from S. D. Fine Chemical Limited (Mumbai, India) and were used as received. Polyvinyl alcohol (PVA) was of molecular weight 30,000 to 70,000 and was supplied by S. D. Fine Chemical Limited. Salts for the preparation of simulated tear fluid were of
Nanoparticle size and zeta potential
The prepared AmB NPs were intended for ocular administration. Thus, particle size and particle size distribution are crucial parameters for safe administration of such a formulation. Particle size for ophthalmic application should not exceed 10 μm.17
The effect of drug:polymer ratio and organic phase:aqueous phase ratio has an immense effect on particle size and distribution. All batches showed a small mean size, well suited for possible ocular application. The mean particle size for drug-loaded
Discussion
In the current study, the potential of Eudragit RL NPs for the specific delivery of antifungal drug to the ocular mucosa was investigated. The advantages of these systems in ocular drug delivery include their ability to contact intimately with the corneal and conjunctival surfaces, thereby increasing delivery to external ocular tissues without compromising inner ocular structures and systemic drug exposure, and to provide these target tissues with long-term drug levels. Consequently, these
References (23)
- et al.
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
Int J Pharm
(1997) - et al.
Poly (e-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity
Int J Pharm
(1997) - et al.
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen
Eur J Pharm Sci
(2002) - et al.
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application
Biomaterials
(2002) - et al.
Lipoaomal amphotericin B is toxic to fungal cells but not to mammalian cells
Biochim Biophys Acta
(1984) - et al.
Nanocapsule formation by interfacial polymer deposition following solvent displacement
Int J Pharm
(1989) - et al.
Microspheres and Nps used in ocular drug delivery systems
Adv Drug Deliv Rev
(1995) - et al.
Haloperidol loaded PLGA nanoparticles: systematic study of particle size and drug content
Int J Pharm
(2007) - et al.
Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles
Int J Pharm
(2005) - et al.
Preparation and characterization of microspheres containing the anti-in.ammatory agents, indomethacin, ibuprofen, and ketoprofen
J Controlled Release
(1989)
Ocular therapy with nanoparticulate systems for controlled drug delivery
J Controlled Release
Cited by (128)
Cationic Polymeric Nanoparticles for Improved Ocular Delivery and Antimycotic Activity of Terconazole
2022, Journal of Pharmaceutical SciencesCitation Excerpt :Mathematical models (zero-order, first-order, Higuchi, and Peppas) were then fit to the release data. The Higuchi model fit the release profiles of TCZ from polymeric NPs best (highest correlation coefficient R2), revealing that the drug followed diffusion-controlled release from the developed NPs, which is consistent with previously reported study findings.24,31 Analysis of the Peppas model data showed the release exponent “n” values ranged between 0.43 and 0.85, revealing a non-Fickian (anomalous) mechanism governed by diffusion and erosion mechanisms.
Formulation and evaluation of brinzolamide encapsulated niosomal in-situ gel for sustained reduction of IOP in rabbits
2022, Journal of Drug Delivery Science and TechnologyOn the feasibility of spray-dried eudragit-trehalose microparticles for enteric drug delivery
2021, International Journal of PharmaceuticsDesign of vincristine sulfate loaded poloxamer in situ nanogel: Formulation and in vitro evaluation
2021, Journal of Drug Delivery Science and Technology
No conflict of interest was reported by the authors of this article.